Prophylaxis against Gallstone Formation with Ursodeoxycholic Acid in Patients Participating in a Very-Low-Calorie Diet Program
| Autor: | Florence F. Vickers, Mitchell L. Shiffman, Gordon D. Kaplan, Valerie Brinkman-Kaplan |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Diet Reducing medicine.drug_class food.diet Gastroenterology Body Mass Index chemistry.chemical_compound food Double-Blind Method Cholelithiasis Risk Factors Weight loss Internal medicine Weight Loss Internal Medicine Bile Humans Medicine In patient Aged Bile acid business.industry Cholesterol Gallbladder Ursodeoxycholic Acid food and beverages General Medicine Middle Aged Ursodeoxycholic acid Very low calorie diet medicine.anatomical_structure chemistry Female medicine.symptom Crystallization Energy Intake business Body mass index medicine.drug |
| Zdroj: | Annals of Internal Medicine. 122:899 |
| ISSN: | 0003-4819 |
| Popis: | To determine whether prophylactic treatment with ursodeoxycholic acid can prevent gallstone formation in persons participating in a very-low-calorie weight reduction diet program.Multicenter, double-blind, placebo-controlled, multidose clinical trial. Patients were treated with placebo or with 300 mg/d, 600 mg/d, or 1200 mg/d of ursodeoxycholic acid.31 Health Management Resources weight management centers.1004 patients were initially enrolled in a 16-week, 520-kcal/d, Health Management Resources liquid protein diet program. All patients had a body mass index of 38 kg/m2 or more and a normal gallbladder ultrasonogram before study entry. Bile analysis was done in 32 patients.Body weight and body mass index were measured before the diet was started and at 2-week intervals for 16 weeks. Gallbladder ultrasonography was done before enrollment and after 8 and 16 weeks of dieting. Bile was obtained by endoscopy and analyzed for cholesterol crystals and lipid levels.Mean body weight for all patients at the start of dieting was 128.2 kg +/- 23.2 kg; mean initial body mass index was 44.2 kg/m2 +/- 6.0 kg/m2. Gallstones developed in 28% (95% CI, 22% to 35%) of patients receiving placebo, in 8% (CI, 5% to 13%) of patients treated with 300 mg/d of ursodeoxycholic acid, in 3% (CI, 1% to 7%) of patients treated with 600 mg/d of ursodeoxycholic acid, and in 2% (CI, 0.5% to 5%) of patients treated with 1200 mg/d of ursodeoxycholic acid. The differences between patients receiving placebo and patients receiving ursodeoxycholic acid were statistically significant. The percentage of ursodeoxycholic acid in bile increased stepwise with increasing doses of ursodeoxycholic acid.Ursodeoxycholic acid, 600 mg/d, is highly effective in preventing gallstone formation in patients having dietary-induced weight reduction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|